Tvardi Therapeutics, Inc. (TVRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has a cash flow conversion efficiency ratio of -0.404x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($14.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tvardi Therapeutics, Inc. (TVRD) total market value for the company's overall valuation and market capitalisation.
Tvardi Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Tvardi Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tvardi Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their cash flow conversion efficiency. Explore how high is Tvardi Therapeutics, Inc.'s earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mistral Iberia Real Estate SOCIMI S.A.
MC:YMIB
|
-0.026x |
|
Pili International Multimedia Co Ltd
TWO:8450
|
0.057x |
|
Estrella Immunopharma Inc.
NASDAQ:ESLA
|
0.240x |
|
Eureka Design Public Company Limited
BK:UREKA
|
0.002x |
|
Fold Holdings, Inc. Class A Common Stock
NASDAQ:FLD
|
-0.181x |
|
Gryphon Digital Mining Inc.
NASDAQ:GRYP
|
0.080x |
|
Is Girisim Sermayesi Yatirim Ortakligi AS
IS:ISGSY
|
-0.007x |
|
CESSATECH A/S DK -20
F:8GN
|
-0.361x |
Annual Cash Flow Conversion Efficiency for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Tvardi Therapeutics, Inc. from 2020 to 2025. View Tvardi Therapeutics, Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.95 Million | $-23.50 Million | -1.122x | -108.46% |
| 2024-12-31 | $-4.59 Million | $-60.92 Million | 13.263x | +3811.96% |
| 2023-12-31 | $-62.06 Million | $-21.04 Million | 0.339x | -14.51% |
| 2022-12-31 | $-45.05 Million | $-17.87 Million | 0.397x | +250.16% |
| 2021-12-31 | $227.52 Million | $-60.09 Million | -0.264x | -1098.46% |
| 2020-12-31 | $249.00 Million | $-5.49 Million | -0.022x | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more